Zai Lab (NASDAQ:ZLAB – Get Rating) had its target price lowered by equities researchers at JPMorgan Chase & Co. from $79.00 to $70.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 106.79% from the company’s current price.
Zai Lab Stock Down 1.2 %
NASDAQ ZLAB opened at $33.85 on Thursday. Zai Lab has a twelve month low of $20.98 and a twelve month high of $53.95. The firm has a market capitalization of $3.31 billion, a PE ratio of -7.31 and a beta of 1.20. The stock’s 50 day moving average is $39.59 and its 200 day moving average is $36.66.
Insider Activity at Zai Lab
In related news, Director William Lis sold 5,434 shares of Zai Lab stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $38.31, for a total transaction of $208,176.54. Following the sale, the director now directly owns 23,330 shares in the company, valued at $893,772.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Zai Lab news, Director William Lis sold 5,434 shares of the business’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $38.31, for a total value of $208,176.54. Following the sale, the director now directly owns 23,330 shares of the company’s stock, valued at $893,772.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Frazor Titus Edmondson III sold 7,965 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $40.55, for a total value of $322,980.75. Following the completion of the sale, the insider now directly owns 19,400 shares in the company, valued at $786,670. The disclosure for this sale can be found here. Insiders have sold 24,879 shares of company stock worth $990,357 over the last ninety days. 6.26% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Zai Lab
Zai Lab Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
- Get a free copy of the StockNews.com research report on Zai Lab (ZLAB)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.